<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"
  dtd-version="1.3" xml:lang="en" article-type="research-article">
  <?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
  <?DTDIdentifier.IdentifierType public?>
  <?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
  <?SourceDTD.Version 1.2?>
  <?ConverterInfo.XSLTName jats2jats3.xsl?>
  <?ConverterInfo.Version 1?>
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="iso-abbrev">Arch Pharm Pract</journal-id>
      <journal-id journal-id-type="publisher-id">archivepp.com</journal-id>
      <journal-id journal-id-type="publisher-id">Arch Pharm Pract</journal-id>
      <journal-title-group>
        <journal-title>Archives of Pharmacy Practice</journal-title>
      </journal-title-group>
      <issn pub-type="epub">2320-5210</issn>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id">archivepp.com-1113</article-id>
      <article-id pub-id-type="doi">10.51847/JHpJjlQV3E</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original research</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>A Review Study on Chronic Inflammatory Demyelinating Polyneuropathy</article-title>
      </title-group>
                  <pub-date pub-type="epub">
        <day>10</day>
        <month>12</month>
        <year>2023</year>
      </pub-date>
      <volume>14</volume>
      <issue>4</issue>
      <fpage>123</fpage>
      <lpage>126</lpage>
      <permissions>
        <copyright-statement>
          Copyright: &#x000a9; 2026 Archives of Pharmacy Practice
        </copyright-statement>
        <copyright-year>2026</copyright-year>
        <license>
          <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/"
            specific-use="textmining" content-type="ccbyncsalicense">
            https://creativecommons.org/licenses/by-nc-sa/4.0/</ali:license_ref>
          <license-p>This is an open access journal, and articles are distributed under the terms of
            the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows
            others to remix, tweak, and build upon the work non-commercially, as long as appropriate
            credit is given and the new creations are licensed under the identical terms.</license-p>
        </license>
      </permissions>
      <abstract>
        <title>A<sc>BSTRACT</sc></title>
        <p>Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare immune-mediated disease in which an abnormal immune response causes demyelination and damage to the axons of peripheral nerves. This study is a systematic review of the literature. The screening of the abstracts was performed on the abstrackrBeta web-based software platform. The etiology, pathogenesis, modern methods of CIDP treatment, as well as the economic consequences of the spread of the disease, reflected in the scientific literature, are considered. Forty five 45 complete texts and nineteen conference procedures were found on the study of disease transmission n 9, humanistic burden n 7, current treatment n 40, and financial burden n 8 of CIDP. Epidemiological study have appeared the frequency and predominance of 0.2 1.6 and 0.8 8.9 per 100,000, depending on topography and symptomatic criteria. Six main types of therapy have been reported in publications on modern treatment methods: intravenous immunoglobulins, subcutaneous immunoglobulins, corticosteroids, plasmapheresis, immunosuppressants, and immunomodulators. According to the analyzed data, indications for the choice between these methods of treatment, as well as dosage regimens and frequency of use, have not been determined. Thus, CIDP is an autoimmune disease that requires constant monitoring and correction of therapy if necessary. </p>
      </abstract>
      <kwd-group>
              </kwd-group>
    </article-meta>
  </front>
</article>